Repurposed drugs and your IP strategy

September 1, 2011Biovista Articles

Using examples of drugs and companies, Dr Andreas Persidis gives tips on how to establish a systematic drug repositioning programme. Online article in the Managing Intellectual Property website. In the absence of productive internal R&D sufficient to support growth, current pharmaceutical IP strategies focus on acquiring smaller biotechs with promising assets to bolster larger pharma’s … Read More

Every drug deserves a second chance

September 1, 2011Biovista Articles

Guest Commentary in Drug Discovery News (DDN) by Andreas Persidis September 2011 After many years of talking about it, the patent cliff is finally with us in a big way. Starting with Pfizer’s Lipitor this coming November, Big Pharma is projected to lose more than $60 billion in the next five to six years from … Read More